open access

Journal of Nanoscience and Nanomaterials

ISSN: 3108-2084 (Online)
DOI Prefix (Crossref): 10.67238

Nanoparticles in the Treatment of Virus- A Broad Study
Review Article - Volume: 2, Issue: 1, 2026 (October)
Sabina Yeasmin* ORCID

Department of Polymer Science & Technology, University of Calcutta, Kolkata, India

*Correspondence to: Sabina Yeasmin, Department of Polymer Science & Technology, University of Calcutta, Kolkata, India, E-Mail:
Received: June 09, 2026; Manuscript No: JNNC-26-2529; Editor Assigned: June 11, 2026; PreQc No: JNNC-26-2529(PQ); Reviewed: June 23, 2026; Revised: August 25, 2026; Manuscript No: JNNC-26-2529(R); Published: October 16, 2026,

ABSTRACT

Viruses impact on healthcare and socioeconomic development. In a public health care system drug resistance are currently are available different therapies. Adverse side effects due to prolonged use is a serious public health concern. Novel treatment strategies developed. The interactions of nanostructures with microorganisms is fast revolutionizing the biomedical field by offering advantages in both diagonostic and therapeutic applications. Nanoparticles have unique properties that can help in drug delivery. The properties of nanoparticles that depend on others are particle size distribution, surface to volume ratio and surface charge depend on encapsulation. This properties can make nanoparticle drug delivery systems to explore therapeutic effects. This review present how to treat viral infections with nanosized materials.

Keywords: Nanosized Materials; Liposomes; Micelles; Viral Infection; Gold Nanoparticles

INTRODUCTION

Infectious disease agents such as bacteria, viruses, fungi and parasites account for approximately 15 million deaths worldwide, with acute respiratory infection and human immunodeficiency virus (HIV) being the leading causes [1,2]. Viral infections can help in both health and socioeconomic development [3]. Drug resistance evolved as it is associated with HIV and influenza infection [4-8]. This phenomenon included morbidity and mortality added costs associated with the use of more expensive drugs and a greater burden to public health systems [2,9]. A novel method develop to treat viral infections.

Nanoparticles are particles that belong to the nanometer range [10,11]. The interaction between nanoscience and biological systems is known as nanobiotechnology [12,13]. It is associated with nanomedicine and diagnose, treatment and prevention of diseases [14].

We are going to introduce here dose limiting biocompatible drugs [15]. For its small size it can invade cell easily [11,16]. Large surface area to volume ratio, surface charge make it a strong weapon to treat viral infections [17,18,19]. Nanoparticles also have some anti-viral properties [20-24]. It also can act as dendrimers [25,26]. It can be able to formation of stable structure [27,28]. It can also modified the structure of polymers [29]. It can also increase stability and the drug retention times [30,31]. This nanoparticles can invade cell and act in the cellular components [30,31,32]. Nanoparticle act as a drug carrier in case of RNA system also. It will act as a carrier in the blood-brain barrier also. It leads to low level replication [33,34]. It also can invade the obstacle and act as a promising tool against membranes [35]. To invade all this problem RNA technology is necessary [36]. The inability of RNA to cross the cell membrane, due to large molecular weight and anionic charge rapid renal clearance, uptake by phagocytes, and toxicity due to stimulated immune response [37,38,39] all present limitations which prohibits their clinical utility. This review will provide an overview of the most recent and relevant literature that describes the application of nanotechnology for the treatment of common viral infections.

Biocompatible Systems

Organic nanoparticles

Organic nanoparticles are most common nanoparticle in drug delivery in humans [40-43]. The most common types of organic nanoparticles are presented below

Polymeric nanoparticles

Polymeric nanoparticles are particles ranging in size from 10-1000 nm. The small size result in capillary penetrations at target sites [44-49]. Polymers approved by the WHO and FDA use in medicine and pharmaceuticals include PLA, PGA and PLGA [50]. PLG and PLGA based nanoparticles are used for biocompatibility and biodegradability purposes [51]. It can interact with serum proteins decrease the opsonization [52,53]. The pharmacokinetic profile and gold-standard of cloaking agent systems can also be represented here [54,55]. Polymeric nanoparticles can be classified as nanocapsules and nanospheres.

Figure 1: Polymeric Nanoparticle Shaped in Spherical Structure

Nanocapsules

In nanocapsules the drug get loaded in the hollow capsules of the inner cavity of polymer. This is coated by some coating range in size from 50 to 300 nm [56]. Nanocapsules can be used as an antiviral agents to cross blood brain barrier [33].

Figure 2: Structure of Nanocapsule

Nanospheres

Nanospheres are matrix that are uniformly dispersed within the size range of 100-200 nm in diameter [56,57]. Hepatitis B virus (HBV), herpes simplex virus (HSV) and influenza are treated by nanospheres [58-62].

Figure 3: Structure of Nanosphere

Liposomes

Liposomes are spherical carriers ranging in size from 20-30 nm [63]. A phospholipid bilayer is there contain an aqueous core [64]. Hydrophilic and lipophilic drugs can also be incorporated into the phospholipid bilayer [65]. It can also be act as an immunological parts [66].

Micelles

Micelles are ranging in size from 10 -100 nm [57]. Polymeric micelles are working as drug delivery agents which have significant therapeutic potential [67-69]. Drug encapsulation with polymeric micelles is one of the most attractive nanotechnologies used to improve both the water solubility and stability of limited drugs [70].

Dendrimers

Dendrimers are symmetrical, macromolecular and hyper-branched structure having connectors and branching units that target environment is controlled by the terminal groups [71]. Central core, branches and functional groups can have the ability to display multivalent surface [72].

Sold Liipid Nanoparticles

Solid lipid nanoparticles are alternative drug delivery system to the conventional colloidal nanoparticles. It can also combine with other nanoparticles and uses in drug delivery systems. Large-scale production of polymeric nanoparticles is a major challenge, production is cost-effective [73]. Stability, safety, availability, decreased toxicity can improve drug-profiles in compared to synthetic polymer nanoparticles [74-76].

Inorganic Nanoparticles

Inorganic nanoparticles are smaller in size than organic nanoparticles [35]. The top-down approach uses chemical or physical methods to reduce the inorganic material to its nanosized form [77].

Figure 4: Structure of Inorganic Nanoparticle

Gold Nanoparticles

Gold nanoparticles (GNPs) are widely researched as nanocarriers due to their excellent conductivity flexibility of surface modification, biocompatibility, and simplistic preparation methods [78]. The unique physical and chemical properties include the gold core, nahotophysical properties and thiol linkages [79,80,81]. During GNPs preparation it can produce versatile ranges of nanoparticles [82-87].

Figure 5: Spherical Structure of Gold Nanoparticles

Silver Nanoparticles

Silver nanoparticles are the most effective of the metallic nanoparticles against bacteria, viruses and other eukaryotic microorganisms, particularly due to the inherent inhibitory and bactericidal potential of silver, but also because of their good conductivity, catalytic properties, and chemical stability [88,89]. The key mechanisms of action of silver nanoparticles are the release of silver ions (which enhances antimicrobial activity), cell membrane disruption, and DNA damage. The reader is referred to a detailed review on the application of silver nanoparticles as virucidal agents [90,91,92].

Figure 6: Structure of Silver Nanoparticles

Other metallic nanoparticles

Various other metallic nanoparticles such as titanium,zinc,and copper, as well as metal oxide nanoparticles such as iron oxide, zinc oxide, and titanium dioxide have demonstrated specific antiviral activities. Others, like platinum nanoparticles, which are used for the detection of influenza virus, are yet to be evaluated [93-97].

Virology

All this nanoparticles are use for the treatment of different viruses [98-103].

 

 

 

Company

Description

Mechanism of action

Indication

Approval year/stage of development

Reference

Inflexal V®

Crucell, Berna Biotech

Virosomal (150 nm liposomes) vaccine

Mimicking native antigen presentation: Liposomes mimic the native virus structure, thus allowing for cellular entry and membrane fusion
Retention of the natural presentation of antigens on liposomal surface provides for high immunogenicity.

Influenza

1997

Herzog,

 Mischler, Metcalfe, Bachmann andJennings [104-106]

Epaxal®

Crucell, Berna Biotech

Inactivated virosomal (liposome) vaccine

Unique mechanism of action which mimics the natural process

HAV

1999

Bovier [107]

PegIntron®

Merck

PEGylated interferon alfa-2b

Improved stability of protein through PEGylation

HCV

2001

Alconcel [108]

Pegasys®

Genentech

PEGylated interferon alfa-2b

Improved stability of protein through PEGylation

HBV, HCV

2002

Alconcel [108]

Influvac® Plus

Solvay Pharma/Abbott

Virosome vaccine

Containing influenza surface proteins neuraminidase and hemagglutinin

Influenza

2005

Waknine [109]

Fluquit TM
(STP 702)

Sirnaomics Inc.

Short interfering RNA
(SiRNA) therapeutic

Gene silencing

H5N1 and H1N1 influenza

Preclinical evaluation

Sirnaomics [110]

Cervisil®
(STP 909)

Sirnaomics Inc.

Short interfering RNA
(SiRNA) therapeutic

Gene silencing

HPV

Preclinical evaluation

Sirnaomics [110]

VivaGel®
(SPL 7013)

Starpharma

Dendrimer

Lysine-based dendrimer with naphthalene disulfonic acid surface groups

HIV, HSV

Clinical trial
(number: NCT00740584) (approved for used against bacterial vaginosis)

Starpharma [111]

DermaVir

Genetic Immunity

Therapeutic vaccine

Synthetic plasmid DNA immunogen expressing 15 antigens, inducing significant expansions of the HIV-specific precursor/memory T cell pool.

HIV

Clinical trial
(number
NCT00270205)

Rodriguez [112]

Doravirine
(MK-1439)

Merck

Solid drug nanoparticle formulation

Non-nucleoside reverse transcriptase inhibitor

HIV

Clinical trial
(number: NCT02549040)

Molina [113]

ARB-001467 TKM-HBV

Arbutus Biopharma

Wet lipid nanoparticle

Lipid particle containing three RNAi
therapeutics that target three sites on the HBV genome

HBV

Clinical trial
(number: NCT02631096)

Seto [114]

CONCLUSION

We can conclude that nanoparticles have antiviral effect also. For its small size it can invade cell easily. The system use for the synthesis of nanoparticles are extremely retain its property on the nanoparticles. Shape is generally spherical. It can invade cell and help in the treatment. We are providing here a lot of result that can reduce silver, gold particles and make them nanoparticles. Spherical nanoparticles have antiviral effect proven in this review. They can cure many diseases. Once it prepared stored in a dark place. So that it stay good for a long time.  If you want to cure viral diseases you can use plant extracts for the preparation of nanoparticles. Will you ever seen such a different type of nanoparticles synthesis and characterization medication and cure for the patient.

REFERENCES

    1. Panáček A, Kolář M, Večeřová R, Prucek R, Soukupová J, Kryštof V, et al.  Antifungal activity of silver nanoparticles against Candida spp. Biomaterials. 2009;30(31):6333-6340. [Crossref] [Google Scholar] [PubMed]
    2. Qasim M, Lim DJ, Park H, Na D.  Nanotechnology for diagnosis and treatment of infectious diseases. J Nanosci Nanotechnol. 2014;14(10):7374-7387. [Crossref] [Google Scholar] [PubMed]
    3. Mehendale R, Joshi M, Patravale VB.  Nanomedicines for treatment of viral diseases. Crit Rev Ther Drug Carrier Syst. 2013;30(1):1-49. [Crossref] [Google Scholar] [PubMed]
    4. Little SJ, Holte S, Routy JP, Mayer KH, Connors M, Walker BD, et al.  Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347(6):385-394. [Crossref] [Google Scholar] [PubMed]
    5. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007;21(2):215-223. [Crossref] [Google Scholar] [PubMed]
    6. Lockhat HA, Silva JR, Alves CN, Lameira J.  Binding free energy calculations of nine FDA-approved protease inhibitors against HIV-1 subtype C I36T† containing 100 amino acids per monomer. Chem Biol Drug Des. 2016;87(4):487-498. [Crossref] [Google Scholar] [PubMed]
    7. Maseko SB, Natarajan S, Sharma V, Bhattacharyya N, Govender T, Sayed Y, et al.  Purification and characterization of naturally occurring HIV-1 (South African subtype C) protease mutants from inclusion bodies. Protein Expr Purif. 2016;122:90-96. [Crossref] [Google Scholar] [PubMed]
    8. Hayden F.  Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis. 2009;48(Suppl 1):S3-S13. [Crossref] [Google Scholar] [PubMed]
    9. Cosgrove SE.  The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42(Suppl 2):S82-S89. [Crossref] [Google Scholar] [PubMed]
    10. Nalwa HS, editor.  Handbook of nanostructured materials and nanotechnology. Vol. 1. San Diego: Academic Press; 1999. p. 1-3. [Google Scholar]
    11. Parboosing R, Maguire GE, Govender P, Kruger HG.  Nanotechnology and the treatment of HIV infection. Viruses. 2012;4(4):488-520. [Crossref] [Google Scholar] [PubMed]
    12. Scheller FW, Bier FF, Pfeiffer D.  Biosensoren: Grundlagen und Anwendungen. Tech Mess. 1995;62(1):213-219. [Crossref] [Google Scholar]
    13. Niemeyer CM, Mirkin CA, editors.  Nanobiotechnology: concepts, applications and perspectives. Vol. 1. Weinheim: Wiley-VCH; 2004. [Google Scholar]
    14. Medepalli KK.  Advanced nanomaterials for biomedical applications [dissertation]. Cambridge: ProQuest; 2008. [Google Scholar]
    15. Schütz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker M.  Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond). 2013;8(3):449-467. [Crossref] [Google Scholar] [PubMed]
    16. Kumar A, Ma H, Zhang X, Huang K, Jin S, Liu J, et al.  Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. Biomaterials. 2012;33(4):1180-1189. [Crossref] [Google Scholar] [PubMed]
    17. McNeil SE.  Unique benefits of nanotechnology to drug delivery and diagnostics. Methods Mol Biol. 2011;697:3-8. [Crossref] [Google Scholar] [PubMed]
    18. Caron J, Reddy LH, Lepêtre-Mouelhi S, Wils P, Desmaële D, Couvreur P.  Squalenoyl nucleoside monophosphate nanoassemblies: new prodrug strategy for the delivery of nucleotide analogues. Bioorg Med Chem Lett. 2010;20(9):2761-2764. [Crossref] [Google Scholar] [PubMed]
    19. Petros RA, DeSimone JM.  Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615-627. [Crossref] [Google Scholar] [PubMed]
    20. Gagliardi M.  Biomimetic and bioinspired nanoparticles for targeted drug delivery. Ther Deliv. 2017;8(5):289-299. [Crossref] [Google Scholar] [PubMed]
    21. Sanvicens N, Marco MP.  Multifunctional nanoparticles – properties and prospects for their use in human medicine. Trends Biotechnol. 2008;26(8):425-433. [Crossref] [Google Scholar] [PubMed]
    22. Bowman MC, Ballard TE, Ackerson CJ, Feldheim DL, Margolis DM, Melander C.  Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Soc. 2008;130(22):6896-6897. [Crossref] [Google Scholar] [PubMed]
    23. Sun RW, Chen R, Chung NP, Ho CM, Lin CL, Che CM.  Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. Chem Commun (Camb). 2005;(40):5059-5061. [Crossref] [Google Scholar] [PubMed]
    24. Lara HH, Ayala-Nuñez NV, Ixtepan-Turrent L, Rodriguez-Padilla C.  Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology. 2010;8:1. [Crossref] [Google Scholar] [PubMed]
    25. Mallipeddi R, Rohan LS.  Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomedicine. 2010;5:533-547. [Crossref] [Google Scholar] [PubMed]
    26. Wang W, Guo Z, Chen Y, Liu T, Jiang L.  Influence of generation 2-5 of PAMAM dendrimer on the inhibition of Tat peptide/TAR RNA binding in HIV-1 transcription. Chem Biol Drug Des. 2006;68(6):314-318. [Crossref] [Google Scholar] [PubMed]
    27. Chiappetta DA, Facorro G, de Celis ER, Sosnik A.  Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine/poloxamer polymeric micelles. Nanomedicine. 2011;7(5):624-637. [Crossref] [Google Scholar] [PubMed]
    28. Goldberg M, Langer R, Jia X.  Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed. 2007;18(3):241-268. [Crossref] [Google Scholar] [PubMed]
    29. Alexis F, Pridgen E, Molnar LK, Farokhzad OC.  Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505-515. [Crossref] [Google Scholar] [PubMed]
    30. Santos-Martinez MJ, Rahme K, Corbalan JJ, Faulkner C, Holmes JD, Tajber L, et al.  Pegylation increases platelet biocompatibility of gold nanoparticles. J Biomed Nanotechnol. 2014;10(6):1004-1015. [Crossref] [Google Scholar] [PubMed]
    31. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54(4):987-992. [Google Scholar] [PubMed]
    32. Muthu MS, Singh S.  Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine (Lond). 2009;4(1):105-118. [Crossref] [Google Scholar] [PubMed]
    33. De Oliveira MP, Garcion E, Venisse N, Benoit JP, Couet W, Olivier JC.  Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (−/−) CF-1 mice. Pharm Res. 2005;22(11):1898-1905. [Crossref] [Google Scholar] [PubMed]
    34. Hellmuth J, Valcour V, Spudich S.  CNS reservoirs for HIV: implications for eradication. J Virus Erad. 2015;1(2):67-71. [Crossref] [Google Scholar] [PubMed]
    35. Mahajan SD, Aalinkeel R, Law WC, Reynolds JL, Nair BB, Sykes DE, et al.  Anti-HIV-1 nanotherapeutics: promises and challenges for the future. Int J Nanomedicine. 2012;7:5301-5314. [Crossref] [Google Scholar] [PubMed]
    36. Duan L, Yan Y, Liu J, Wang B, Li P, Hu Q, et al.  Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis C. Sci Rep. 2016;6:24867. [Crossref] [Google Scholar] [PubMed]
    37. Adesina SK, Akala EO.  Nanotechnology approaches for the delivery of exogenous siRNA for HIV therapy. Mol Pharm. 2015;12(12):4175-4187. [Crossref] [Google Scholar] [PubMed]
    38. Chen BM, Su YC, Chang CJ, Burnouf PA, Chuang KH, Chen CH, et al.  Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. Anal Chem. 2016;88(21):10661-10666. [Crossref] [Google Scholar] [PubMed]
    39. Toub N, Malvy C, Fattal E, Couvreur P.  Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed Pharmacother. 2006;60(9):607-620. [Crossref] [Google Scholar] [PubMed]
    40. Bawa R.  Nanopharmaceuticals: nanopharmaceuticals. Eur J Nanomed. 2010;3(1):34-40. [Crossref] [Google Scholar]
    41. Walsh TJ, Viviani MA, Arathoon E, Chiou C, Ghannoum M, Groll AH, et al.  New targets and delivery systems for antifungal therapy. Med Mycol. 2000;38(Suppl 1):335-347. [Google Scholar] [PubMed]
    42. Dobrovolskaia MA, McNeil SE.  Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2007;2(8):469-478. [Crossref] [Google Scholar] [PubMed]
    43. Zazo H, Colino CI, Lanao JM.  Current applications of nanoparticles in infectious diseases. J Control Release. 2016;224:86-102. [Crossref] [Google Scholar] [PubMed]
    44. Mora-Huertas CE, Fessi H, Elaissari A.  Polymer-based nanocapsules for drug delivery. Int J Pharm. 2010;385(1-2):113-142. [Crossref] [Google Scholar] [PubMed]
    45. Baram-Pinto D, Shukla S, Richman M, Gedanken A, Rahimipour S, Sarid R.  Surface-modified protein nanospheres as potential antiviral agents. Chem Commun (Camb). 2012;48(66):8359-8361. [Crossref] [Google Scholar] [PubMed]
    46. Bergeron MG, Desormeaux A.  Liposomes encapsulating antiviral drugs. US Patent 5,773,027. 1998. [Google Scholar]
    47. Dutta T, Agashe HB, Garg M, Balasubramanium P, Kabra M, Jain NK.  Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J Drug Target. 2007;15(1):89-98. [Crossref] [Google Scholar] [PubMed]
    48. Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA.  Gold nanoparticles for biology and medicine. Angew Chem Int Ed Engl. 2010;49(19):3280-3294. [Crossref] [Google Scholar] [PubMed]
    49. Ochekpe NA, Olorunfemi PO, Ngwuluka NC.  Nanotechnology and drug delivery part 2: nanostructures for drug delivery. Trop J Pharm Res. 2009;8(3):275-287. [Crossref] [Google Scholar]
    50. Stevanovic M, Uskokovic D.  Poly (lactide-co-glycolide)-based micro and nanoparticles for the controlled drug delivery of vitamins. Curr Nanosci. 2009;5(1):1-14. [Crossref] [Google Scholar]
    51. Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, et al.  Nanoparticle vaccines. Vaccine. 2014;32(3):327-337. [Crossref] [Google Scholar] [PubMed]
    52. Aggarwal P, Hall JB, McClelland CB, Dobrovolskaia MA, McNeil SE.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev. 2009;61(6):428-437. [Crossref] [Google Scholar] [PubMed]
    53. Kovochich M, Marsden MD, Zack JA.  Activation of latent HIV using drug-loaded nanoparticles. PLoS One. 2011;6(4):e18270. [Crossref] [Google Scholar] [PubMed]
    54. Santos-Magalhães NS, Mosqueira VCF.  Nanotechnology applied to the treatment of malaria. Adv Drug Deliv Rev. 2010;62(5):560-575. [Crossref] [Google Scholar] [PubMed]
    55. Mignani S, Majoral JP.  Dendrimers as macromolecular tools to tackle from colon to brain tumor types: a concise overview. New J Chem. 2013;37(11):3337-3357. [Crossref] [Google Scholar]
    56. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE.  Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1-2):1-20. [Crossref] [Google Scholar] [PubMed]
    57. Letchford K, Burt H.  A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm. 2007;65(3):259-269. [Crossref] [Google Scholar] [PubMed]
    58. Zeng P, Xu Y, Zeng C, Ren H, Peng M.  Chitosan-modified poly (D, L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing. Int J Pharm. 2011;415(1-2):259-266. [Crossref] [Google Scholar] [PubMed]
    59. Dehghan S, Kheiri MT, Tabatabaiean M, Darabi S, Tafaghodi M.  Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization. Arch Pharm Res. 2013;36(8):981-992. [Crossref] [Google Scholar] [PubMed]
    60. Mohajer M, Khameneh B, Tafaghodi M.  Preparation and characterization of PLGA nanospheres loaded with inactivated influenza virus, CpG-ODN and Quillaja saponin. Iran J Basic Med Sci. 2014;17(9):722-726. [Google Scholar] [PubMed]
    61. Gregory AE, Williamson D, Titball R.  Vaccine delivery using nanoparticles. Front Cell Infect Microbiol. 2013;3:13. [Crossref] [Google Scholar] [PubMed]
    62. Thorley AJ, Tetley TD.  New perspectives in nanomedicine. Pharmacol Ther. 2013;140(2):176-185. [Crossref] [Google Scholar] [PubMed]
    63. Kuntworbe N, Martini N, Shaw J, Al-Kassas R.  Malaria intervention policies and pharmaceutical nanotechnology as a potential tool for malaria management. Drug Dev Res. 2012;73(4):167-184. [Crossref] [Google Scholar]
    64. Amin R. Nanotechnology in controlling infectious disease. In: Hunter RJ, Preedy VR, editors.  Nanomedicine in health and disease. Enfield, NH: Science Publishers; 2011. p. 167-183. [Google Scholar]
    65. Garnett MC.  Targeted drug conjugates: principles and progress. Adv Drug Deliv Rev. 2001;53(2):171-216. [Crossref] [Google Scholar] [PubMed]
    66. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW.  Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm. 2008;364(2):272-280. [Crossref] [Google Scholar] [PubMed]
    67. Kabanov AV, Batrakova EV, Alakhov VY.  Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release. 2002;82(2-3):189-212. [Crossref] [Google Scholar] [PubMed]
    68. Arifin DR, Palmer AF.  Polymersome encapsulated hemoglobin: a novel type of oxygen carrier. Biomacromolecules. 2005;6(4):2172-2181. [Crossref] [Google Scholar] [PubMed]
    69. Zhang L, Gu F, Chan J, Wang A, Langer R, Farokhzad O.  Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761-769. [Crossref] [Google Scholar] [PubMed]
    70. Moretton MA, Glisoni RJ, Chiappetta DA, Sosnik A.  Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles. Colloids Surf B Biointerfaces. 2010;79(2):467-479. [Crossref] [Google Scholar] [PubMed]
    71. Sahoo SK, Labhasetwar V.  Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003;8(24):1112-1120. [Crossref] [Google Scholar] [PubMed]
    72. Caminade AM, Laurent R, Majoral JP.  Characterization of dendrimers. Adv Drug Deliv Rev. 2005;57(15):2130-2146. [Crossref] [Google Scholar] [PubMed]
    73. Müller RH, Mäder K, Gohla S.  Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177. [Crossref] [Google Scholar] [PubMed]
    74. Gupta U, Jain NK.  Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv Drug Deliv Rev. 2010;62(4-5):478-490. [Crossref] [Google Scholar] [PubMed]
    75. Patel PA, Patravale VB.  AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. J Biomed Nanotechnol. 2011;7(5):632-639. [Crossref] [Google Scholar] [PubMed]
    76. Xie S, Tao Y, Pan Y, Qu W, Cheng G, Huang L, et al.  Biodegradable nanoparticles for intracellular delivery of antimicrobial agents. J Control Release. 2014;187:101-117. [Crossref] [Google Scholar] [PubMed]
    77. Thakkar KN, Mhatre SS, Parikh RY.  Biological synthesis of metallic nanoparticles. Nanomedicine. 2010;6(2):257-262. [Crossref] [Google Scholar] [PubMed]
    78. Cui Y, Zhao Y, Tian Y, Zhang W, Lü X, Jiang X.  The molecular mechanism of action of bactericidal gold nanoparticles on Escherichia coli. Biomaterials. 2012;33(7):2327-2333. [Crossref] [Google Scholar] [PubMed]
    79. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD.  Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small. 2005;1(3):325-327. [Crossref] [Google Scholar] [PubMed]
    80. Skirtach AG, Muñoz Javier A, Kreft O, Köhler K, Piera Alberola A, Möhwald H, et al.  Laser-induced release of encapsulated materials inside living cells. Angew Chem Int Ed Engl. 2006;45(28):4612-4617. [Crossref] [Google Scholar] [PubMed]
    81. Ghosh P, Han G, De M, Kim CK, Rotello VM.  Gold nanoparticles in delivery applications. Adv Drug Deliv Rev. 2008;60(11):1307-1315. [Crossref] [Google Scholar] [PubMed]
    82. Schmid G.  Large clusters and colloids. Metals in the embryonic state. Chem Rev. 1992;92(8):1709-1727. [Crossref] [Google Scholar]
    83. Brust M, Walker M, Bethell D, Schiffrin DJ, Whyman R.  Synthesis of thiol-derivatised gold nanoparticles in a two-phase liquid–liquid system. J Chem Soc Chem Commun. 1994;(7):801-802. [Crossref] [Google Scholar]
    84. Templeton AC, Wuelfing WP, Murray RW.  Monolayer-protected cluster molecules. Acc Chem Res. 2000;33(1):27-36. [Crossref] [Google Scholar] [PubMed]
    85. Turkevich J, Stevenson PC, Hillier J.  A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss Faraday Soc. 1951;11:55-75. [Crossref] [Google Scholar]
    86. Frens G.  Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions. Nature. 1973;241(105):20-22. [Crossref] [Google Scholar]
    87. Grabar KC, Freeman RG, Hommer MB, Natan MJ.  Preparation and characterization of Au colloid monolayers. Anal Chem. 1995;67(4):735-743. [Crossref] [Google Scholar]
    88. Gong P, Li H, He X, Wang K, Hu J, Tan W, et al.  Preparation and antibacterial activity of Fe3O4@Ag nanoparticles. Nanotechnology. 2007;18(28):285604. [Crossref] [Google Scholar]
    89. Cho KH, Park JE, Osaka T, Park SG.  The study of antimicrobial activity and preservative effects of nanosilver ingredient. Electrochim Acta. 2005;51(5):956-960. [Crossref] [Google Scholar]
    90. Rai M, Yadav A, Gade A.  Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv. 2009;27(1):76-83. [Crossref] [Google Scholar] [PubMed]
    91. Huh AJ, Kwon YJ.  'Nanoantibiotics': a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Control Release. 2011;156(2):128-145. [Crossref] [Google Scholar] [PubMed]
    92. Lara HH, Garza-Treviño EN, Ixtepan-Turrent L, Singh DK.  Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds. J Nanobiotechnology. 2011;9:30. [Crossref] [Google Scholar] [PubMed]
    93. Gerrity D, Ryu H, Crittenden J, Abbaszadegan M.  Photocatalytic inactivation of viruses using titanium dioxide nanoparticles and low-pressure UV light. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2008;43(12):1261-1270. [Crossref] [Google Scholar] [PubMed]
    94. Antoine TE, Mishra YK, Trigilio J, Tiwari V, Adelung R, Shukla D.  Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection. Antiviral Res. 2012;96(3):363-375. [Crossref] [Google Scholar] [PubMed]
    95. Ingle AP, Duran N, Rai M.  Bioactivity, mechanism of action, and cytotoxicity of copper-based nanoparticles: a review. Appl Microbiol Biotechnol. 2014;98(3):1001-1009. [Crossref] [Google Scholar] [PubMed]
    96. Yadavalli T, Shukla D.  Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections. Nanomedicine (Lond). 2017;13(1):219-230. [Crossref] [Google Scholar] [PubMed]
    97. Yang ZH, Zhuo Y, Yuan R, Chai YQ.  An amplified electrochemical immunosensor based on in situ-produced 1-naphthol as electroactive substance and graphene oxide and Pt nanoparticles functionalized CeO2 nanocomposites as signal enhancer. Biosens Bioelectron. 2015;69:321-327. [Crossref] [Google Scholar] [PubMed]
    98. Chaudhuri RG, Paria S.  Core/shell nanoparticles: classes, properties, synthesis mechanisms, characterization, and applications. Chem Rev. 2012;112(4):2373-2433. [Crossref] [Google Scholar] [PubMed]
    99. Tojo C, Buceta D, López-Quintela MA.  Core-shell nanocatalysts obtained in reverse micelles: structural and kinetic aspects. J Nanomater. 2015;2015:1-10. [Crossref] [Google Scholar]
    100. Chatterjee K, Sarkar S, Rao KJ, Paria S.  Core/shell nanoparticles in biomedical applications. Adv Colloid Interface Sci. 2014;209:8-39. [Crossref] [Google Scholar] [PubMed]
    101. Cheong S, Ferguson P, Hermans IF, Jameson GN, Tilley RD.  Synthesis and stability of highly crystalline and stable iron/iron oxide core/shell nanoparticles for biomedical applications. ChemPlusChem. 2012;77(2):135-140. [Crossref] [Google Scholar]
    102. Varanda LC, Imaizumi M, Santos FJ, Jafelicci M.  Iron oxide versus Fe55Pt45/Fe3O4: improved magnetic properties of core/shell nanoparticles for biomedical applications. IEEE Trans Magn. 2008;44(11):4448-4451. [Crossref] [Google Scholar]
    103. Arias JL, López-Viota M, Ruiz MA, López-Viota J, Delgado AV.  Development of carbonyl iron/ethylcellulose core/shell nanoparticles for biomedical applications. Int J Pharm. 2007;339(1-2):237-245. [Crossref] [Google Scholar] [PubMed]
    104. Herzog C, Hartmann K, Künzi V, Kursteiner O, Mischler R, Lazar H, et al.  Eleven years of Inflexal® V – a virosomal adjuvanted influenza vaccine. Vaccine. 2009;27(33):4381-4387. [Crossref] [Google Scholar] [PubMed]
    105. Mischler R, Metcalfe IC.  Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine. 2002;20(Suppl 5):B17-B23. [Crossref] [Google Scholar] [PubMed]
    106. Bachmann MF, Jennings GT.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787-796. [Crossref] [Google Scholar] [PubMed]
    107. Bovier PA.  Epaxal®: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines. 2008;7(8):1141-1150. [Crossref] [Google Scholar] [PubMed]
    108. Alconcel SNS, Baas AS, Maynard HD.  FDA-approved poly(ethylene glycol)–protein conjugate drugs. Polym Chem. 2011;2(7):1442-1448. [Crossref] [Google Scholar]
    109. Waknine Y.  International approvals: Avalox IV, Pegasys, Influvac. Medscape. 2005. [Google Scholar]
    110. Sirnaomics.  Advancing RNAi therapeutics. 2016. Accessed November 24, 2016. [Google Scholar]
    111. Starpharma.  VivaGel active against Zika virus. 2016. Accessed October 10, 2016. [Google Scholar]
    112. Rodriguez B, Asmuth DM, Matining RM, Spritzler J, Jacobson JM, MaWhinney S, et al.  Safety, tolerability and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial. J Acquir Immune Defic Syndr. 2013;64(4):351-359. [Crossref] [Google Scholar] [PubMed]
    113. Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine is non-inferior to darunavir/r in phase 3 treatment-naive trial at week 48. In:  Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections (CROI 2017). Seattle, WA; February 13-16, 2017. Abstract 45LB. [Google Scholar]
    114. Seto WK, Yuen MF.  New pharmacological approaches to a functional cure of hepatitis B. Clin Liver Dis. 2016;8(4):83-88. [Crossref] [Google Scholar] [PubMed]
Citation: Yeasmin S (2026). Nanoparticles in the Treatment of Virus- A Broad Study. J. Nanosci. Nanomater. Vol.2 Iss.1, October (2026), pp:85-91.
Copyright: © 2026 Sabina Yeasmin. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
×

Contact Emails

nanoscience@confmeets.net
support@confmeets.com
finance@confmeets.com
editorial@confmeets.com

Article Processing Timeline

2-5 Days Initial Quality & Plagiarism Check
25-35
Days
Peer Review Feedback
45-60 Days Total article processing time

EDITORIAL & PUBLICATION INFORMATION

English Publication Language
Single-Blind Peer-Review Model
17% Acceptance Rate
<18% Similarity Screening Guideline
Open Access Access Model

All manuscripts undergo editorial assessment and originality screening as part of the journal's evaluation process. The acceptance rate shown is based on journal-level editorial data and may change over time. Similarity reports are assessed editorially and are not interpreted solely on the basis of a numerical similarity score.

Why Publish with us?

  • Rigorous Peer Review
  • Rapid Publication
  • Global Open Access
  • Crossref DOI
  • International Editorial Board
  • Global Visibility
  • Plagiarism Screening
  • Dedicated Author Support
  • Special Issues
  • Transparent Publication Process
  • High Publishing Standards
  • Worldwide Research Community
  • Journal Flyer

    Flyer Image